Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)

Completed

Conditions studied: Coronary Artery Disease

In brief

Researchers hope that this new non-invasive multi-detector scanner (DSCT) will provide diagnostic information comparable to the combination of traditional SPECT (for function and blood flow) and CT imaging (for a precise anatomical view).

Key facts

Study ID

NCT00892307

Run by

Cedars-Sinai Medical Center

People needed

34

Starts

2007-02-01

Expected to finish

2011-05-01

Last updated by the study team

2013-11-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provide written consent and are willing to comply with protocol requirements
• Are at least 18 years of age
• Are referred for clinically-ordered SPECT
• Have known CAD

You may not qualify if…

• Patients being referred to invasive coronary angiography will not be included in this pilot
• Caffeine intake within the 24 hours prior to adenosine stress testing
• Pregnancy (known or suspected)
• Intolerance or contraindication to adenosine (severe Asthma…)
• Intake of methylxanthine containing medications such as theophylline that have not been withdrawn and would interfere with the effectiveness of adenosine.
• Unstable coronary syndromes
• Uncontrolled congestive cardiac failure or cardiogenic shock
• Uncontrolled hypertension with resting BP > 200/110
• More than 30 days between the Adeno-SPECT and the Adeno-DSCT
• Revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery) between the Adeno-SPECT and the Adeno-DSCT
• Change in clinical status as determined by the investigator
• Inability to be on same medication regime 24 hrs prior to Adeno-SPECT and Adeno DSCT
• Patients with chronic renal failure (C.C.T. < 60 ml/m2/sec)
• Patients with allergy to contrast iodinated media
• Congestive heart failure
• History of thromboembolic disorders
• Multiple myeloma
• Hyperthyroidism
• Pheochromocytoma
• Atrial fibrillation
• Inability to perform breath hold for 12 seconds
• Pilot 2:
• All inclusions/exclusions are the same as Pilot 1, WITH THE ADDITION OF:
• Inclusion Criteria:
• Have had prior (within 30 days) positive Adeno-SPECT scan

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.